Fulcrum Therapeutics Announces CEO Transition


Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor

Bryan E. Stuart promoted to president and chief executive officer effective March 31, 2021

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan E. Stuart, the company's chief operating officer, will become Fulcrum's president and chief executive officer and will be appointed to the Board of Directors. Mr. Stuart will succeed current president and chief executive officer Robert J. Gould, Ph.D. who will be retiring as of March 31, 2021. Dr. Gould will remain as a member of the Board of Directors and will serve as an advisor to the company. Additionally, Mark Levin, Fulcrum's Board chair, will assume the role of executive chair effective upon Dr. Gould's retirement.

“On behalf of the entire Board, I want to thank Robert for his leadership and dedication to Fulcrum,” said Mark Levin. “Robert joined us as CEO in 2016 and was instrumental in ensuring Fulcrum's successful launch. His decades of experience and steadfast dedication have positioned Fulcrum to make significant and rapid progress in its goal to create therapies for genetically defined rare diseases. We wish Robert the best in his retirement and are grateful that he will continue to be a member …

Full story available on Benzinga.com


Please enter your comment!
Please enter your name here